Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment

References

• Badesch DB Champion HC Sanchez MA Diagnosis and assessment of pulmonary arterial hypertension J Am Coll Cardiol 2009 54 1 Suppl S55 S66 19555859
   PubMed Web of Science ®Google Scholar
• McLaughlin VV Archer SL Badesch DB ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation 2009 119 16 2250 2294 19332472
   PubMed Web of Science ®Google Scholar
• Barst RJ McGoon M Torbicki A Diagnosis and differential assessment of pulmonary arterial hypertension J Am Coll Cardiol 2004 43 12 Suppl S 40S 47S 15194177
   PubMed Web of Science ®Google Scholar
• Sitbon O Humbert M Jais X Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation 2005 111 23 3105 3111 15939821
   PubMed Web of Science ®Google Scholar
• Torres F Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension Int J Clin Pract 2007 61 10 1756 1765 17877662
   PubMed Web of Science ®Google Scholar
• Godinas L Guignabert C Seferian A Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Semin Respir Crit Care Med 2013 34 5 714 724 24037637
   PubMed Web of Science ®Google Scholar
• Nakamura K Akagi S Sarashina T Ogawa A Matsubara H Ito H Treatment with imatinib for refractory PAH Nihon Yakurigaku Zasshi 2014 143 4 173 177 Japanese 24717604
   PubMedGoogle Scholar
• Toba M Alzoubi A O’Neill K A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension Am J Pathol 2014 184 2 369 375 24401613
   PubMed Web of Science ®Google Scholar
• Arita S Arita N Hikasa Y Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs Can Vet J 2013 54 3 255 261 23997262
   PubMed Web of Science ®Google Scholar
• Pankey EA Thammasiboon S Lasker GF Baber S Lasky JA Kadowitz PJ Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat Am J Physiol Heart Circ Physiol 2013 305 9 H1288 H1296 23997103
   PubMed Web of Science ®Google Scholar
• Mucke H The role of imatinib in the treatment of pulmonary hypertension Drugs Today (Barc) 2013 49 3 203 211 23527324
   PubMed Web of Science ®Google Scholar
• Domvri K Zarogoulidis P Darwiche K Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy J Cancer 2013 4 9 736 754 24312144
   PubMed Web of Science ®Google Scholar
• Zarogoulidis K Zarogoulidis P Darwiche K Treatment of non-small cell lung cancer (NSCLC) J Thorac Dis 2013 5 Suppl 4 S389 S396 24102012
   PubMed Web of Science ®Google Scholar
• Souza R Sitbon O Parent F Simonneau G Humbert M Long term imatinib treatment in pulmonary arterial hypertension Thorax 2006 61 8 736 16877696
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Darwiche K Huang H Time recall; future concept of chronomodulating chemotherapy for cancer Curr Pharm Biotechnol 2013 14 6 632 642 24180308
   PubMed Web of Science ®Google Scholar
• Zaric B Stojsic V Tepavac A Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC) J Thorac Dis 2013 5 Suppl 4 S371 S377 24102009
   PubMed Web of Science ®Google Scholar
• Boukovinas I Tsakiridis K Zarogoulidis P Neo-adjuvant chemotherapy in early stage non-small cell lung cancer J Thorac Dis 2013 5 Suppl 4 S446 S448 24102019
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Petridis D Ritzoulis C Internal mouthpiece designs as a future perspective for enhanced aerosol deposition. Comparative results for aerosol chemotherapy and aerosol antibiotics Int J Pharm 2013 456 2 325 331 24035789
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Kioumis I Ritzoulis C New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam Int J Pharm 2013 455 1–2 182 188 23891745
   PubMed Web of Science ®Google Scholar
• Ulivi P Zoli W Capelli L Chiadini E Calistri D Amadori D Target therapy in NSCLC patients: relevant clinical agents and tumour molecular characterisation Mol Clin Oncol 2013 1 4 575 581 24649213
   PubMedGoogle Scholar
• Madhusudan S Ganesan TS Tyrosine kinase inhibitors and cancer therapy Recent Results Cancer Res 2007 172 25 44 17607934
   PubMedGoogle Scholar
• Madhusudan S Ganesan TS Tyrosine kinase inhibitors in cancer therapy Clin Biochem 2004 37 7 618 635 15234243
   PubMed Web of Science ®Google Scholar
• Abe K Toba M Alzoubi A Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats Am J Respir Cell Mol Biol 2011 45 4 804 808 21378262
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Darwiche K Yarmus L Defense mechanisms of the respiratory system and aerosol production systems Med Chem 2014 10 2 123 136 24007475
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Papanas N Kouliatsis G Spyratos D Zarogoulidis K Maltezos E Inhaled insulin: too soon to be forgotten? J Aerosol Med Pulm Drug Deliv 2011 24 5 213 223 21689020
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Eleftheriadou E Sapardanis I Feasibility and effectiveness of inhaled carboplatin in NSCLC patients Invest New Drugs 2012 30 4 1628 1640 21739158
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Petridis D Ritzoulis C Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup Int J Pharm 2013 453 2 480 487 23769993
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Darwiche K Krauss L Inhaled cisplatin deposition and distribution in lymph nodes in stage II lung cancer patients Future Oncol 2013 9 9 1307 1313 23980678
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Chatzaki E Porpodis K Inhaled chemotherapy in lung cancer: future concept of nanomedicine Int J Nanomedicine 2012 7 1551 1572 22619512
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Petridis D Ritzoulis C Further experimentation of inhaled; Lantus, Actrapid and Humulin with todays’ production systems Int J Pharm 2013 458 1 39 47 24140545
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Kioumis I Porpodis K Clinical experimentation with aerosol antibiotics: current and future methods of administration Drug Des Devel Ther 2013 7 1115 1134
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Giraleli C Karamanos NK Inhaled chemotherapy in lung cancer: safety concerns of nanocomplexes delivered Ther Deliv 2012 3 9 1021 1023 23035587
   PubMedGoogle Scholar
• Darwiche K Zarogoulidis P Karamanos NK Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology Future Oncol 2013 9 4 505 525 23560374
   PubMed Web of Science ®Google Scholar
• Clay MM Pavia D Newman SP Clarke SW Factors influencing the size distribution of aerosols from jet nebulisers Thorax 1983 38 10 755 759 6648854
   PubMed Web of Science ®Google Scholar
• Kendrick AH Smith EC Wilson RS Selecting and using nebuliser equipment Thorax 1997 52 Suppl 2 S92 S101 9155861
   PubMed Web of Science ®Google Scholar
• Hoffmann N Duft D Kiselev A Leisner T Contact freezing efficiency of mineral dust aerosols studied in an electrodynamic balance: quantitative size and temperature dependence for illite particles Faraday Discuss 2013 165 383 390 24601013
   PubMed Web of Science ®Google Scholar
• Newman SP Pellow PG Clay MM Clarke SW Evaluation of jet nebulisers for use with gentamicin solution Thorax 1985 40 9 671 676 4060108
   PubMed Web of Science ®Google Scholar
• Davis JM Davies IA Some physico-chemical characteristics of the antigens of Ehrlich ascites-tumour cells Biochem Soc Trans 1980 8 4 436 437 7450169
   PubMed Web of Science ®Google Scholar
• Buttini F Miozzi M Balducci AG Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers Int J Pharm 2014 465 1–2 42 51 24491530
   PubMed Web of Science ®Google Scholar
• Kendrick AH Smith EC Denyer J Nebulizers – fill volume, residual volume and matching of nebulizer to compressor Respir Med 1995 89 3 157 159 7746906
   PubMed Web of Science ®Google Scholar
• Kwok PC Trietsch SJ Kumon M Chan HK Electrostatic charge characteristics of jet nebulized aerosols J Aerosol Med Pulm Drug Deliv 2010 23 3 149 159 20500092
   PubMed Web of Science ®Google Scholar
• Hardie WD Davidson C Ikegami M EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol 2008 294 6 L1217 L1225 18424623
   PubMed Web of Science ®Google Scholar
• Toby IT Chicoine LG Cui H Chen B Nelin LD Hypoxia-induced proliferation of human pulmonary microvascular endothelial cells depends on epidermal growth factor receptor tyrosine kinase activation Am J Physiol Lung Cell Mol Physiol 2010 298 4 L600 L606 20139181
   PubMed Web of Science ®Google Scholar
• Woodruff PG Wolff M Hohlfeld JM Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease Am J Respir Crit Care Med 2010 181 5 438 445 20007923
   PubMed Web of Science ®Google Scholar
• Kobayashi M Kubota T Uemura Y Taguchi H A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib Respirology 2009 14 2 302 304 19192229
   PubMed Web of Science ®Google Scholar
• Klein M Schermuly RT Ellinghaus P Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling Circulation 2008 118 20 2081 2090 18955668
   PubMed Web of Science ®Google Scholar
• Moreno-Vinasco L Gomberg-Maitland M Maitland ML Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension Physiol Genomics 2008 33 2 278 291 18303084
   PubMed Web of Science ®Google Scholar
• Krauth MT Binder T Ohler L Jager U Valent P Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy Leuk Res 2008 32 11 1779 1783 18417214
   PubMed Web of Science ®Google Scholar
• Ghofrani HA Morrell NW Hoeper MM Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy Am J Respir Crit Care Med 2010 182 9 1171 1177 20581169
   PubMed Web of Science ®Google Scholar
• Ciuclan L Hussey MJ Burton V Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression Am J Respir Crit Care Med 2013 187 1 78 89 23087024
   PubMed Web of Science ®Google Scholar
• Tang JR Markham NE Lin YJ Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor Am J Physiol Lung Cell Mol Physiol 2004 287 2 L344 L351 15064225
   PubMed Web of Science ®Google Scholar
• Le Cras TD Markham NE Tuder RM Voelkel NF Abman SH Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure Am J Physiol Lung Cell Mol Physiol 2002 283 3 L555 L562 12169575
   PubMed Web of Science ®Google Scholar
• Grimminger F Schermuly RT PDGF receptor and its antagonists: role in treatment of PAH Adv Exp Med Biol 2010 661 435 446 20204747
   PubMed Web of Science ®Google Scholar
• Nakamura K Akagi S Ogawa A Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension Int J Cardiol 2012 159 2 100 106 21376411
   PubMed Web of Science ®Google Scholar
• Kosanovic D Schermuly R Are tyrosine kinase inhibitors the better serotonin inhibitors? Am J Respir Crit Care Med 2013 187 1 4 5 23281348
   PubMed Web of Science ®Google Scholar
• Ziino AJ Ivanovska J Belcastro R Effects of rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia Pediatr Res 2010 67 2 177 182 19858775
   PubMed Web of Science ®Google Scholar
• Oka M Homma N Taraseviciene-Stewart L Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats Circ Res 2007 100 6 923 929 17332430
   PubMed Web of Science ®Google Scholar
• Ryczek R Gora-Tybor J Betkier-Lipinska K Cwetsch A Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma Pol Merkur Lekarski 2013 34 204 342 344 Polish 23882932
   PubMedGoogle Scholar
• Hennigs JK Keller G Baumann HJ Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011 11 30 21605451
   PubMed Web of Science ®Google Scholar
• Shah RR Morganroth J Shah DR Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval) Drug Saf 2013 36 5 295 316 23620167
   PubMed Web of Science ®Google Scholar
• Dasanu CA Padmanabhan P Clark BA3rd Do C Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use Expert Opin Drug Saf 2012 11 3 445 457 22469002
   PubMed Web of Science ®Google Scholar
• Norman P A novel Syk kinase inhibitor suitable for inhalation: R-343(?) – WO-2009031011 Expert Opin Ther Pat 2009 19 10 1469 1472 19552507
   PubMed Web of Science ®Google Scholar
• Houssaini A Abid S Mouraret N Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension Am J Respir Cell Mol Biol 2013 48 5 568 577 23470622
   PubMed Web of Science ®Google Scholar
• Pullamsetti SS Berghausen EM Dabral S Role of Src tyrosine kinases in experimental pulmonary hypertension Arterioscler Thromb Vasc Biol 2012 32 6 1354 1365 22516066
   PubMed Web of Science ®Google Scholar